



Alzinova recruits Kirsten Harting as new Chief Medical Officer

Alzinova AB (publ) ("Alzinova" or the "Company") announces today that the Company has recruited Kirsten Harting as new Chief Medical Officer (CMO). The role includes overall responsibility for the continued clinical development of the drug candidate ALZ-101 and the antibody ALZ-201. Kirsten will be part of the Company's management team and will start her position on August 14.

Alzinova works with the development of Alzheimer's drugs and has developed a unique approach to counteract the disease that can have a major impact on the care and prevention of Alzheimer's disease. The Company's goal is to take its drug candidates through clinical studies and to the market and become a market leader in the treatment of the disease. Alzinova is now taking another important step in this direction by recruiting Kirsten Harting as Chief Medical Officer (CMO).

Kirsten Harting has a medical degree, an executive MBA from Copenhagen Business School and more than 30 years of experience in medicine, clinical studies and drug development as well as business development and bringing products to market from Lundbeck, Pfizer, ALK and Novo Nordisk, among others. Kirsten comes from the role as Senior Medical Director at Cytoki Pharma and will start her position as CMO at Alzinova on August 14.

"We are very pleased to welcome Kirsten Harting to the Alzinova team as our new Chief Medical Officer. Her extensive knowledge and expertise in medicine, clinical studies and business development, combined with her experience in the pharmaceutical industry, is incredibly valuable for Alzinova's future development", says Kristina Torfgård, CEO of Alzinova.

"I am really looking forward to joining Alzinova. The Company already has an opportunity to take a strong position in the market, and I believe that Alzinova's drug candidates can have a significant impact on patients, relatives and healthcare professionals. My role at Alzinova will focus on being the patient's voice in the Company's management team and ensuring that we conduct clinical studies in the best possible way and thus get great results and eventually see the drug on the market", says Kirsten Harding.

For more information, please contact:

Kristina Torfgård, CEO

Tel. +46 708 46 79 75

E-mail: kristina.torfgard@alzinova.com

Please note that this is an English translation of a press release written in Swedish by Alzinova AB (publ), in the event of any inaccuracies, the Swedish version applies.



About Alzinova

Alzinova AB is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer's disease targeting toxic amyloid beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova's proprietary A β CC peptide™ technology enables the development of disease-modifying treatments that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer's is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company's Certified Adviser on Nasdaq First North Growth Market is Redeye AB. For more information about Alzinova, please visit: www.alzinova.com

Attachments

Alzinova recruits Kirsten Harting as new Chief Medical Officer